Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"glargine"”.
-
Physiology and pharmacology of diabetes therapies in the cat: insulin detemir, insulin glargine, exenatide and the incretin effect
… insulin analogs, insulin detemir and insulin glargine. An analog-sensitive insulin ELISA was used at the same time to measure exogenous insulin concentrations. We also used the isoglycemic clamp method to study the pharmacodynamics of the GLP-1 mimetic, exenatide. An exenatide-specific ELISA …
-
Controlled Release of Insulin and Modified Insulin from a Novel Injectable Biodegradable Gel
… release of insulin from the gels, <br />insulin glargine particles were purified from commercially available Lantus® formulation. <br />The freeze dried insulin glargine particles were then loaded into the blank gels and tested <em>in vivo</em>. The formulation prepared with 5% PLGA (i.v. 0.09, …
-
A cost-utility and budget impact analysis of long-acting insulin analogues, (determir, glargine and degludec) for the treatment of adults with T1DM in South Africa
… the newer long-acting insulin analogues detemir, glargine and degludec have yet to be performed in the South African public health sector context. Methods: A systematic search for clinical evidence was performed to inform the economic evaluation. A cost-utility analysis was carried out utilising …
-
Assessment and Treatment of Impaired Insulin- Secretion and Action in Type 2 Diabetes
… a TZD (pioglitazone) and a long-acting insulin (glargine) as add-on in the treatment of patients with T2D, not achieving glycaemic goals when treated with classic anti-diabetic agents on glycaemic control, insulin sensitivity, β-cell function and markers of increased cardiovascular load (Papers …
-
Trends in Prices of Insulin Marketed in the US
… (biosimilar) insulins; long-acting insulin glargine and rapid-acting insulin lispro experienced a negative adjusted CAGR (-1.20%, -33.70%, respectively). Insulin acquisition cost and reimbursement amounts showed a large variation when compared with the average wholesale (AWP) prices. The …